It aims to explore the efficacy of ziltivekimab, administered subcutaneously once a month for 4 years, in reducing MACE in patients with chronic kidney disease (CKD), elevated CRP, and evidence of atherosclerotic cardiovascular disease [60]. Here, CRP is linked to chronic kidney disease.